Medical Device Assessment and Procurement - Fair and Efficient Access in Countries with Limited Health Budgets

Ernesto Nogueira
ValueConnected
The Hague, Netherlands

Claudia Wild
LBI-HTA
Vienna, Austria

Rok Hren
University of Ljubljana
Ljubljana, Slovenia

Bence Takács
OGYEI
Budapest, Hungary
Medical Device Assessment and Procurement - Fair and Efficient Access in Countries with Limited Health Budgets

Ernesto Nogueira, MBA
ValueConnected
The Hague, Netherlands
Medical Device Assessment and Procurement—Fair and Efficient Access in Countries with Limited Health Budgets

Claudia Wild, PhD
LBI-HTA
Vienna, Austria
EUnetHTA
European Network for Health Technology Assessment

!! HTA on Medical Devices in Europe: European Collaboration !!

Claudia Wild, Director LBI-HTA
Planned and ongoing projects (POP) database

around 900 ongoing projects in Europe (at any time)

POP statistics as of March 2019: 868 projects in 44 agencies (20 countries):
88 topics overlapping (= 10% identical topics, STA):
54 for 2 agencies, 22 for 3 agencies, 9 for 4 agencies and 3 for 5 agencies!

225 similar projects (= 26% same indication, MTA)
Type of use (medical device HTA)

- Most agencies add additional information
- Compared with pharmaceuticals more agencies are able to use the assessments with either no changes or translation only
EUnetHTA intentions:

- To reduce overlap and duplication of effort and hence
- To promote more effective use of HTA-resources: increase efficiency
- To facilitate good practice in HTA methods and processes (capacity building, methodological consistency, harmonization of reporting)
Medical Device Assessment and Procurement—Fair and Efficient Access in Countries with Limited Health Budgets

Claudia Wild, PhD
LBI-HTA
Vienna, Austria
Medical Device Assessment and Procurement - Fair and Efficient Access in Countries with Limited Health Budgets

Rok Hren, PhD, MSc
University of Ljubljana
Ljubljana, Slovenia
From oligopoly to monopoly

The tender dossier sets out the criteria for the most economically advantageous offer on the basis of scoring - a total of 100 points.

Price offered for a system - 60 points, defined by the equation: (the lowest bidding price) / (price of the provider) * 60

Four technical categories of the system - up to 40 points

<table>
<thead>
<tr>
<th>System</th>
<th>Financial part - points</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>Technical specification - total</th>
<th>Total points</th>
</tr>
</thead>
<tbody>
<tr>
<td>Provider R</td>
<td>485.000&lt;br&gt;42,06</td>
<td>8</td>
<td>6</td>
<td>6</td>
<td>20&lt;br&gt;40</td>
<td>82,06</td>
</tr>
<tr>
<td>Provider J</td>
<td>380.000&lt;br&gt;53,68</td>
<td>4</td>
<td>6</td>
<td>4</td>
<td>14&lt;br&gt;28</td>
<td>81,68</td>
</tr>
<tr>
<td>Provider G</td>
<td>350.000&lt;br&gt;58,29</td>
<td>2</td>
<td>6</td>
<td>2</td>
<td>12&lt;br&gt;22</td>
<td>80,29</td>
</tr>
<tr>
<td>Provider P</td>
<td>340.000&lt;br&gt;60,00</td>
<td>0</td>
<td>4</td>
<td>4</td>
<td>14&lt;br&gt;22</td>
<td>82,00</td>
</tr>
</tbody>
</table>
### From costs of tests to costs of diagnostics

<table>
<thead>
<tr>
<th>Monitoring HbA1c</th>
<th>Germany</th>
<th>Belgium</th>
<th>Switzerland</th>
</tr>
</thead>
<tbody>
<tr>
<td>LD HbA1c test cost</td>
<td>0.5 €</td>
<td>1 €</td>
<td>1 €</td>
</tr>
<tr>
<td>LD test follow-up cost</td>
<td>5 €</td>
<td>5 €</td>
<td>10 €</td>
</tr>
<tr>
<td>POC HbA1c test cost</td>
<td>3.5 €</td>
<td>4.5 €</td>
<td>4 €</td>
</tr>
<tr>
<td>POC test follow-up cost</td>
<td>0 €</td>
<td>0 €</td>
<td>0 €</td>
</tr>
</tbody>
</table>

Navarro F, Hren R, Boltyenkov A. Budget Impact Analysis (BIA) of Point-of-Care of HBA1C Monitoring in Belgian, German and Swiss Patients with Diabetes Mellitus Type II. Value in Health, vol. 21, S164, 2018.
Medical Device Assessment and Procurement - Fair and Efficient Access in Countries with Limited Health Budgets

Rok Hren, PhD, MSc
University of Ljubljana
Ljubljana, Slovenia
Medical Device Assessment and Procurement—Fair and Efficient Access in Countries with Limited Health Budgets

Bence Takács
OGYEI
Budapest, Hungary
Important to note:

- We are critically appraising manufacturer submissions (no self-initiated procedures)
- The department issues advisory documents, the decision is made at ministerial/NHIF level
Other Technologies (Class III) Reimbursement Procedure

- MAH
- National Health Insurance Fund (NHIF)
- NIPN Division for Medical Device Evaluation
- National Health Insurance Fund (NHIF)
- Professional Board advice
- NIPN Department for HTA critical appraisal
- NIHF pre-review
- Scientific Board advice
- Legislation
- Ministry of Human Capacities (MoHC)
- NHIF DG referral
- NHIF appraisal
- Technology Appraisal Committee (TAC)

Bence Takács MSc, ISPOR Warsaw 2019
Medical Device Assessment and Procurement-Fair and Efficient Access in Countries with Limited Health Budgets

Bence Takács
OGYEI
Budapest, Hungary
Medical Device Assessment and Procurement - Fair and Efficient Access in Countries with Limited Health Budgets

Ernesto Nogueira
ValueConnected
The Hague, Netherlands

Claudia Wild
LBI-HTA
Vienna, Austria

Rok Hren
University of Ljubljana
Ljubljana, Slovenia

Bence Takács
OGYEI
Budapest, Hungary